Blue Note's products will serve all cancer patients, from early stage through survivorship, in both the in-patient and out-patient settings.
|Product Candidate||Disease Progression||Development||Proof of Concept||Pivotal Trial||FDA Review|
|BNT001||Early - Mid Stage||✕||✕||✕|
|Product Candidate||Disease Progression||Status|
|BNT001||Early - Mid Stage||2|
Blue Note Therapeutics is honored to work with the National Comprehensive Cancer Network (NCCN) and other leading cancer care organizations in our quest to help cancer patients live better.